A practical reference on Stenabolic: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-03-20 and is reviewed periodically as new material appears.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule ligand; not a hormone or peptide |
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| CAS Registry Number | 1379686-30-2 | Unique chemical identifier |
| Common synonyms | SR9009; stenabolic | Stenabolic is informal and not an official name |
| Reported targets | REV-ERBα and REV-ERBβ | Nuclear receptors linked to circadian and metabolic regulation |
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
== Background == Yu was born in Beijing, China. She received a master's degree in ancient Chinese literature and a doctoral degree in film & TV studies from Beijing Normal University. She holds strategist/researcher positions in a roster of mass media groups such as China Television Artists Association, China Visual Association's Tertiary Arts committee, China Visual Association's Research Group, CCTV's Research Office, China News Research Group, China-Guangdong Research Institute, China-Guangdong Institute Legal Programs Committee, News Corp (Australia), etc. Yu is apparently a fan of pop music idols such as Jay Chou and Nan Quan Mama, a Chinese classic enthusiast and a Kunqu Opera performer. She is also unofficially known as "the chieftain of the fun-seeking club of the School of Media and Arts at Beijing Normal University."
Speaking on BBC Radio 4's The Today Podcast, television presenter Dame Esther Rantzen, who has been diagnosed with stage four lung cancer, reveals that she has joined the Dignitas organisation and plans to "buzz off to Zurich" if her treatment does not work. Her comments reopen the debate about assisted dying in the United Kingdom. 19 December The UK government publishes new guidelines advising schools in England on how to deal with pupils who wish to change their gender, be known under a different name or wear a different uniform, urging schools to "take a very cautious approach" and to inform parents of any gender related issues. DNA profiling of a 2,000-year-old skeleton unearthed in Cambridgeshire provides evidence that a nomadic race of people from Southern Russia, known as Sarmatians, travelled to Britain during the Roman era. Independent and former Conservative MP Peter Bone loses his seat following a recall petition, triggering a by-election in Wellingborough. The British Museum signs a £50m deal with BP to help it fund a major renovation project. 20 December Data from the Office for National Statistics shows UK inflation fell to 3.9% in November 2023, the lowest for more than two years, down from 4.6% the previous month. The fall, which is sharper than expected, is largely attributed to fuel and food costs declining and household goods prices 'slowing'. The Bank of England's target for inflation is 2%.
=== Laboratory findings === Hormonal syndromes should be confirmed with laboratory testing. Laboratory findings in Cushing syndrome include increased serum glucose (blood sugar) and increased urine cortisol. Adrenal virilism is confirmed by the finding of an excess of serum androstenedione and dehydroepiandrosterone. Findings in Conn syndrome include low serum potassium, low plasma renin activity, and high serum aldosterone. Feminization is confirmed with the finding of excess serum estrogen.
King also encouraged private importers and traders, opened a public brewery in 1804, and introduced a schedule of values for Indian copper and Spanish pieces of eight which were used as currency. There was still a serious problem keeping the coin in the colony, despite it being valued higher than its face value. King's actions were not wholly effective but they still antagonised officers of the Corps. Like Hunter, he was the subject of pamphlets and attacks. King tried, unsuccessfully, to court-martial the officers responsible.
Sources: en.wikipedia.org
== Applications == The highest selling transdermal patch in the United States is the nicotine patch, which releases nicotine in controlled doses to help with cessation of tobacco smoking. The first commercially available vapour patch to reduce smoking was approved in Europe in 2007. Two opioid medications used to provide round-the-clock relief for severe pain are often prescribed in patch form, fentanyl CII (marketed as Duragesic) and buprenorphine CIII (marketed as BuTrans). Hormonal patches: Estrogen patches are sometimes prescribed to treat menopausal symptoms (as well as post-menopausal osteoporosis) and to transgender women as a type of hormone replacement therapy. Contraceptive patches (marketed as Ortho Evra or Evra) and Testosterone CIII patches for both men (Androderm) and women (Intrinsa). Nitroglycerin patches are sometimes prescribed for the treatment of angina in lieu of sublingual pills. Transdermal scopolamine is commonly used as a treatment for motion sickness. The anti-hypertensive drug clonidine is available in transdermal patch form. Emsam, a transdermal form of the MAOI selegiline, became the first transdermal delivery agent for an antidepressant approved for use in the U.S. in March 2006. Daytrana, the first methylphenidate transdermal delivery system for the treatment of attention deficit hyperactivity disorder (ADHD), was approved by the FDA in April 2006. Secuado, a transdermal form of the atypical antipsychotic asenapine, was approved by the FDA in October 2019.
Vicryl (polyglactin 910) is an absorbable, synthetic, usually braided suture, manufactured by Ethicon Inc., a subsidiary of Johnson and Johnson. A monofilament version is also made for use in ophthalmic practice. It is indicated for soft tissue approximation and ligation. The suture holds its tensile strength for approximately two to three weeks in tissue and is completely absorbed by acid hydrolysis within 8-10 weeks. Vicryl and other polyglycolic-acid sutures may also be treated for more rapid breakdown ("Vicryl Rapide") in rapidly healing tissues such as mucous membrane or impregnated with triclosan ("Vicryl Plus Antibacterial") to provide antimicrobial protection of the suture line. Because Vicryl is slow-absorbing and often braided, its use is contraindicated in the closure of any cutaneous wound exposed to the air, as it draws moisture from the healing tissue to the skin and allows bacteria and irritants to migrate into the wound. This may lead to high reactivity to the contaminants, poor wound healing, and eventually infection. Although the name "Vicryl" is a trademark of Ethicon, the term "vicryl" has been used generically referring to any synthetic absorbable suture made primarily of polyglycolic acid. Other brands of polyglycolic acid suture include PolySyn, Surgicryl, Polysorb, and Dexon, all of which are manufactured by different companies. Vicryl is a copolymer of lactide (a bislactone of lactic acid) and glycolide (a bislactone of glycolic acid).
On 1 April, North Korean public health official Pak Myong-su stated that North Korea had no cases of the virus. Edwin Salvador, the WHO's representative in North Korea, reported that as of 2 April, 709 people had been tested, with no confirmed cases, and 509 people were in quarantine. On 23 April, it was reported that the country had conducted 740 COVID-19 tests, and all of them came back negative. The same day, Daily NK reported that a defecting North Korean who was shot by a Chinese border guard while attempting to cross the Tumen River into China tested positive for the virus, and was under quarantine in a Chinese hospital. On 11 April, Kim Jong Un presided over a meeting of the Politburo of the Workers' Party of Korea. The meeting adopted a joint resolution by the Central Committee, State Affairs Commission, and the Cabinet, "on more thoroughly taking national measures for protecting the life and safety of our people from the worldwide epidemic disease". The resolution called to take strict national countermeasures to thoroughly check the inroads of the virus due to the steady spread of the epidemic. From mid to late April, restrictions on foreigners travelling in Pyongyang were relaxed, Nampo harbour was reopened to container ships, and the 14th Supreme People's Assembly with hundreds of delegates was held without the wearing of face masks. On 23 April, US analyst website 38 North reported that North Korea's early and extensive response appeared to be successful in containing the virus.
Sources: en.wikipedia.org
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.
No. It has no approved medical indication, and human safety and efficacy data are limited. It appears in research chemical markets and is banned by some sports authorities.
Natural ligands include heme and certain metabolites; SR9009 is a synthetic small molecule with higher potency and selectivity in some assays. Its effects depend on cell type and timing. It is not a naturally occurring compound.
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.